File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Blockade of VEGF/VEGFR pathway enhances chemo-sensitivity in hepatocellular carcinoma

TitleBlockade of VEGF/VEGFR pathway enhances chemo-sensitivity in hepatocellular carcinoma
Authors
Issue Date2007
PublisherAmerican Association for Cancer Research
Citation
AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, 22–26 October, 2007. In Molecular Cancer Therapeutics, 2007, v. 6 n.11S, p. A202 How to Cite?
AbstractBackground: Systemic and local chemotherapy for hepatocellular carcinoma (HCC) remains a tough task due to chemo-resistance of tumor cells to cytotoxic agents. Interaction between vascular endothelial growth factor (VEGF) and its receptors plays an important role in the proliferation and survival of tumor cells. Since HCC cells express high levels of VEGF and VEGFRs, we postulate that VEGF/VEGFR pathway might be involved in chemo-resistance of tumor cells to cytotoxic agents. Methods: In vitro, HCC cell lines with wild type (wt) p53 (HepG2), mutant/null p53 (PLC/Hep3B) and p53 stable transfectant (Hep3B/p53+) were treated with cisplatin, VEGF, PTK787 (a VEGFR inhibitor), and cisplatin combined with PTK787, respectively. Cell apoptosis was determined by Annexin V/PI staining, and the mechanism of cell death was explored by poly(ADP-ribose) polymerase (PARP) degradation, and alterations in pro-apoptotic and anti-apoptotic molecules. In vivo, the effects of PTK787 combined with cisplatin was evaluated in a HCC xenograft model in nude mice. Results: The three HCC cell lines express different levels of VEGFRs, Flt-1 and Flk-1. PTK787 enhanced cisplatin-induced PARP degradation and apoptosis in all the three cell lines tested, especially in PLC cells. PTK787, or cisplatin alone down-regulated the expression of pro-survival molecules, cyclin D1 and Bcl-2, and a synergistic effect was observed when PTK787 was combined with cisplatin. Administration of VEGF recombinant protein could abrogate the synergistic effects of PTK787 and cisplatin. VEGF treatment stimulated up-regulation of survivin in tumor cells, while knockdown of survivin reversed the protective effects of VEGF on cisplatin-induced cell apoptosis. Prominent retardation of tumor growth was observed in the HCC xenografts treated with PTK787 and cisplatin in vivo. Conclusions: This study demonstrated that VEGF/VEGFR pathway played an important role in protecting tumor cells from cisplatin-induced cell death, and blockade of VEGF/VEGFR pathway could enhance cisplatin-induced chemo-cytotoxicity in HCC.
Persistent Identifierhttp://hdl.handle.net/10722/108237
ISSN
2015 Impact Factor: 5.579
2015 SCImago Journal Rankings: 3.224

 

DC FieldValueLanguage
dc.contributor.authorYang, Zen_HK
dc.contributor.authorKok, TWen_HK
dc.contributor.authorOr, YYYen_HK
dc.contributor.authorNg, NPen_HK
dc.contributor.authorTam, KHen_HK
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorFan, STen_HK
dc.date.accessioned2010-09-26T00:31:12Z-
dc.date.available2010-09-26T00:31:12Z-
dc.date.issued2007en_HK
dc.identifier.citationAACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, 22–26 October, 2007. In Molecular Cancer Therapeutics, 2007, v. 6 n.11S, p. A202-
dc.identifier.issn1535-7163-
dc.identifier.urihttp://hdl.handle.net/10722/108237-
dc.description.abstractBackground: Systemic and local chemotherapy for hepatocellular carcinoma (HCC) remains a tough task due to chemo-resistance of tumor cells to cytotoxic agents. Interaction between vascular endothelial growth factor (VEGF) and its receptors plays an important role in the proliferation and survival of tumor cells. Since HCC cells express high levels of VEGF and VEGFRs, we postulate that VEGF/VEGFR pathway might be involved in chemo-resistance of tumor cells to cytotoxic agents. Methods: In vitro, HCC cell lines with wild type (wt) p53 (HepG2), mutant/null p53 (PLC/Hep3B) and p53 stable transfectant (Hep3B/p53+) were treated with cisplatin, VEGF, PTK787 (a VEGFR inhibitor), and cisplatin combined with PTK787, respectively. Cell apoptosis was determined by Annexin V/PI staining, and the mechanism of cell death was explored by poly(ADP-ribose) polymerase (PARP) degradation, and alterations in pro-apoptotic and anti-apoptotic molecules. In vivo, the effects of PTK787 combined with cisplatin was evaluated in a HCC xenograft model in nude mice. Results: The three HCC cell lines express different levels of VEGFRs, Flt-1 and Flk-1. PTK787 enhanced cisplatin-induced PARP degradation and apoptosis in all the three cell lines tested, especially in PLC cells. PTK787, or cisplatin alone down-regulated the expression of pro-survival molecules, cyclin D1 and Bcl-2, and a synergistic effect was observed when PTK787 was combined with cisplatin. Administration of VEGF recombinant protein could abrogate the synergistic effects of PTK787 and cisplatin. VEGF treatment stimulated up-regulation of survivin in tumor cells, while knockdown of survivin reversed the protective effects of VEGF on cisplatin-induced cell apoptosis. Prominent retardation of tumor growth was observed in the HCC xenografts treated with PTK787 and cisplatin in vivo. Conclusions: This study demonstrated that VEGF/VEGFR pathway played an important role in protecting tumor cells from cisplatin-induced cell death, and blockade of VEGF/VEGFR pathway could enhance cisplatin-induced chemo-cytotoxicity in HCC.-
dc.languageengen_HK
dc.publisherAmerican Association for Cancer Research-
dc.relation.ispartofMolecular Cancer Therapeuticsen_HK
dc.titleBlockade of VEGF/VEGFR pathway enhances chemo-sensitivity in hepatocellular carcinomaen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailYang, Z: zfyang@hkucc.hku.hken_HK
dc.identifier.emailOr, YYY: yvonnekin@gmail.comen_HK
dc.identifier.emailNg, NP: michaelnpng@gmail.comen_HK
dc.identifier.emailTam, KH: chrishku@graduate.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.identifier.hkuros139182en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats